West Pharmaceutical Services Inc

West Pharmaceutical Services Inc (WST) Stock Analysis

$337.470

-8.403 (-2.49%)At close

Loading chart…
High
345.870
Open
344.510
VWAP
339.82
Vol
496.40K
Mkt Cap
23.95B
Low
336.130
Amount
168.69M
EV/EBITDA, TTM
24.57

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.

AI analysis of West Pharmaceutical Services Inc (WST)

buy

West Pharmaceutical Services Inc is a good buy right now due to its current price of $337.47, which is significantly lower than the analyst price targets ranging from $410 to $425. The company has shown strong financial performance with a gross margin of 37.74% in Q2 2026 and a year-to-date change of +22.09%, indicating robust growth. However, the main risk is the RSI of 22.07, suggesting that the stock is oversold and may face short-term volatility.

Analyst Ratings (7)

+3.33% upside
Buy
4 Buy
2 Hold
1 Sell
Current: 337.47
Low
285.00
Average
348.70
High
375.00

Citi

2026-08-03

Price Target

$412

Buy

Evercore ISI

2026-07-27

Price Target

$425

Outperform

BofA

2026-07-24

Price Target

$410

Buy

Evercore ISI

2026-07-23

Price Target

$410

Outperform

TD Cowen

2026-07-15

Price Target

$410

Buy

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST) is 39.68, compared to its 5-year average forward P/E of 41.62.

Forward P/E

Fair
5Y Average P/E
41.62
Current P/E
39.68
Overvalued
48.62
Undervalued
34.63

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
27.08
Current EV/EBITDA
24.57
Overvalued
32.16
Undervalued
22.00

Forward P/S

Fair
5Y Average P/S
7.61
Current P/S
6.79
Overvalued
9.29
Undervalued
5.94

Alphio AI Price Scenarios for WST

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%WST

$201.68

Scenario price

B

Base

Base · 50%WST

$194.98

Scenario price

B

Bear

Bear · 25%WST

$174.26

Scenario price

Whales holding WST

V

Vestal Point Capital, LP

+ HoldingWST

+10.94%

3M Return

A

Artisan Partners Limited Partnership

+ HoldingWST

+8.81%

3M Return

G

Generation Investment Management LLP

+ HoldingWST

+8.20%

3M Return

D

D.F. Dent and Company, Inc.

+ HoldingWST

+5.94%

3M Return

K

Kayne Anderson Rudnick Investment Management, LLC

+ HoldingWST

+5.84%

3M Return

L

Longview Partners (Guernsey) Limited

+ HoldingWST

+5.80%

3M Return

Events Timeline

2026-07-23 (ET)

09:30:00

Dow, S&P 500, and Nasdaq Futures Decline

06:30:00

Company Reports Q2 Revenue of $872.3M, Exceeding Expectations

06:30:00

Sees Q3 Revenue of $820M-$835M

06:30:00

Company Raises FY26 Revenue Outlook to $3.35B-$3.38B

2026-06-01 (ET)

16:40:00

West Pharmaceutical Appoints Michel Lagarde as CEO

News

WST FAQ — answered by Alphio AI

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

West Pharmaceutical Services Inc is a good buy right now due to its current price of $337.47, which is significantly lower than the analyst price targets ranging from $410 to $425. The company has shown strong financial performance with a gross margin of 37.74% in Q2 2026 and a year-to-date change of +22.09%, indicating robust growth. However, the main risk is the RSI of 22.07, suggesting that the stock is oversold and may face short-term volatility.

7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める